![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Once-monthly islatravir has no meaningful effect
on exposure to long-acting reversible contraceptives (LARCs)
|
|
|
EACS 2023 Oct 18
Michelle Pham*; Prachi Wickremasingha; Ryan Vargo; Munjal Patel; Katherine Nedrow;
Brenda Homony; Michael Robertson; Rebeca M. Plank
Merck & Co., Inc., Rahway, NJ, USA
*Presenting author
An employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, at the time of the study
![1023231](../images/102323/102323-17/1023231.gif)
![1023232](../images/102323/102323-17/1023232.gif)
![1023233](../images/102323/102323-17/1023233.gif)
![1023234](../images/102323/102323-17/1023234.gif)
![1023235](../images/102323/102323-17/1023235.gif)
![1023236](../images/102323/102323-17/1023236.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|